If You Invested in Tharimmune Inc (THAR)

Tharimmune, Inc. (NASDAQ: THAR) is a clinical-stage biotechnology company that has also adopted a digital asset treasury strategy. According to company disclosures, Tharimmune develops therapeutic candidates in immunology, inflammation, oncology and other areas of critical unmet medical need, while at the same time leveraging Canton Coin (CC) to support the Canton Network and the digitization of traditional financial markets.

Tharimmune is described in multiple press releases as a clinical-stage biotechnology company with a diverse pipeline. Its lead clinical asset, TH104, is a buccal film formulation of nalmefene, an opioid antagonist. TH104 is being developed via a 505(b)(2) New Drug Application (NDA) pathway for a specific indication: temporary prophylaxis of respiratory and/or nervous system depression in military personnel and chemical incident responders who may enter environments contaminated with high-potency opioids such as fentanyl and related analogues. Company communications emphasize TH104’s intended role as a national security medical countermeasure against weaponized or high-potency opioids.

Beyond this primary indication, Tharimmune has disclosed additional planned indications for TH104, including chronic pruritus in primary biliary cholangitis (PBC), a rare liver disease characterized by debilitating itch. The company has also reported that TH104’s buccal film delivery is designed for non-injectable, rapid absorption and convenient administration, which may be useful for first responders who could be wearing protective gear.

Tharimmune’s pipeline also includes TH023, which the company describes as a novel oral monoclonal antibody program targeting tumor necrosis factor-alpha (TNF-alpha). TH023 is being developed as a new approach to treating autoimmune and inflammatory diseases. Company disclosures state that TH023 originated from a global licensing agreement with Intract Pharma for a program initially known as INT-023 and is based on a proprietary protease enzyme-stabilized platform (Soteria®) for oral antibody delivery. Preclinical work described by Tharimmune indicates that the platform has demonstrated oral delivery of infliximab in animal models, with systemic and local tissue exposure.

In oncology, Tharimmune reports an early-stage multispecific biologic platform that targets unique epitopes across multiple solid tumors through its proprietary EpiClick™ Technology. The company has a license agreement with OmniAb, Inc. to access antibody discovery technology for specified disease markers, supporting its immuno-oncology and autoimmune disease programs. These disclosures position Tharimmune’s research focus around immunology, inflammation, oncology, autoimmune disease, and national security-related countermeasures.

In parallel with its biotechnology activities, Tharimmune has adopted what it calls a differentiated digital asset treasury (DAT) strategy. Company press releases state that Tharimmune is the first publicly traded company to leverage Canton Coin and support the Canton Network with the goal of advancing institutional blockchain adoption and the digitization of financial markets. The company has entered into private placement transactions and related agreements to acquire CC and to build a Canton Coin treasury. Disclosures describe plans to apply to operate as a Super Validator and to run additional validators on the Canton Network, as well as to invest in applications built on the network that aim to increase institutional utility and adoption across capital markets.

Tharimmune’s filings and press releases explain that this DAT strategy is intended to generate value through activities on the Canton Network, including holding CC and participating in network validation and application ecosystems. The company notes that it is the first and only publicly traded company supported by the Canton Foundation, the governing body overseeing the Canton Network, and that prominent institutional investors and market participants have taken part in its private placement transactions related to this strategy.

Corporate updates and proxy materials describe Tharimmune as a Nasdaq-listed company that has undertaken equity financings, a registered direct offering, an at-the-market (ATM) program, and a large private placement to support both its historical biotechnology operations and its Canton Coin treasury strategy. SEC filings detail material definitive agreements, securities purchase agreements, warrant amendments, and an increase in authorized common stock, reflecting a capital structure designed to support ongoing R&D and the DAT strategy.

Business Model and Segments

Based on the company’s own descriptions, Tharimmune’s activities can be viewed in two main areas:

• Biotechnology R&D: Clinical-stage development of TH104 for national security and other indications, development of TH023 for oral antibody delivery targeting TNF-alpha, and work on an early-stage multispecific biologic platform using EpiClick™ Technology, supported by a license agreement with OmniAb.
• Digital Asset Treasury and Blockchain Participation: Acquisition and holding of Canton Coin, planned validator operations and Super Validator applications on the Canton Network, and strategic investments in Canton-based applications, all framed as a digital asset treasury strategy aligned with institutional blockchain adoption.

Regulatory and Clinical Milestones

Tharimmune has reported positive feedback from the U.S. Food and Drug Administration (FDA) regarding TH104. In news releases, the company states that the FDA has concurred with its pharmacokinetic modeling plan for TH104 as a prophylactic countermeasure against respiratory depression from fentanyl and other ultrapotent opioids, and that FDA feedback indicates no additional clinical trials appear necessary prior to a 505(b)(2) NDA submission for a specified indication in military personnel and chemical incident responders. The company has also described positive pharmacokinetic simulation results for TH104 and has highlighted intellectual property protection for its transmucosal nalmefene film technology in multiple jurisdictions.

These regulatory and IP developments are presented by Tharimmune as key steps toward advancing TH104 as a national security solution and as a platform for broader indications, including chronic pruritus in PBC and other conditions involving severe itch associated with chronic liver and kidney diseases.

Corporate Governance and Capital Actions

SEC filings show that Tharimmune has undertaken several corporate actions, including:

• Increasing authorized shares of common stock through an amendment to its certificate of incorporation.
• Amending its omnibus equity incentive plan to increase shares reserved for issuance.
• Entering into at-the-market and private placement arrangements to issue common stock and pre-funded warrants.
• Appointing new executive leadership, including a Chief Executive Officer and President associated with the digital asset treasury strategy, and later a Chief Financial Officer with capital markets and financial operations experience.

These steps are described in filings and proxy materials as measures to support financing flexibility, employee incentives, and the execution of both its biotechnology and digital asset strategies.

Frequently Asked Questions about Tharimmune, Inc.

The following FAQs are based solely on the company’s own public descriptions in press releases and SEC filings.